他汀类药物在慢性心力衰竭中的作用

当前有关研究显示,他汀类药物对慢性心力衰竭有预防和治疗作用,其机制可能与他汀类药物的多效性有关。他汀类药物在慢性心力衰竭中的作用包括改善内皮功能、抗氧化、抗炎、调节神经内分泌、抑制心室重构、抗血栓等。     

他汀降胆固醇预防冠心病临床分析

目的 探讨他汀降胆固醇预防冠心病的临床效果.方法 对冠心病患者他汀类药物降胆固醇预防临床资料进行回顾性分析.结果 采用他汀类药物降脂治疗,以降低LDL-C,使其达到〈100 mg/dl（2.6 mmol/L）.TC、LDL、TG明显降低,及高密度脂蛋白升高.结论 他汀类药物能有效降低TC和LDL-C,还有延缓斑块进展,使斑块稳定和抗炎等调脂以外的作用.所有冠心病患者,无论其血脂水平如何,均应给予他汀类药物.     

他汀类药物与心力衰竭

他汀类药物的多效性作用使其在心力衰竭治疗中发挥重要作用。他汀类药物治疗心力衰竭的机制与抗氧化、抗心肌肥厚、改善血管内皮功能、抗炎症、抗动脉粥样硬化、抗神经激素内分泌激活、促进祖代细胞进入外周循环等有关。已有临床研究表明他汀类药物对心力衰竭治疗有利。     

他汀类药物多效性对心肌的保护作用进展

目的 探讨他汀类药物的多效性对心肌的保护作用,为合理应用该类药物提供参考.方法 查阅近期相关文献资料,对他汀类药物的多效性作用进行综合分析.结果 他汀类药物除调脂作用外,还具有抗氧化、抗炎、抗血栓、改善血管内皮功能等多效性作用.结论 他汀类药物的多效性作用对心肌具有保护作用,临床可用于心肌疾病的预防和治疗.     

他汀类药物多效药理作用及其机制研究进展

他汀类是临床上治疗高胆固醇血症主要药物, 广泛应用于冠心病一级及二级预防。近年来研究表明,他汀类药物还具有降脂外的多重作用,包括改善血管内皮功能、抗炎症、抗氧化作用、稳定动脉粥样硬化和抗肿瘤作用等。本文围绕他汀类药物对血管疾病和肿瘤的作用及机制展开综述。     

他汀类药物的临床新应用概述

他汀类药物是HMG—COA还原酶抑制药,具有良好的降脂效果,其作用机制主要是通过竞争抑制HMG—COA还原酶,减少胆固醇生物合成。近年来许多国内外资料显示,他汀类药物对机体的保护作用远远超出了其降脂作用。现已发现其在改善内皮细胞功能、抑制细胞增殖、抗炎、促进骨质形成等方面有显著疗效,尤其在抗炎及促骨质形成这两方面,许多研究学者将其抗炎作用更多的运用于呼吸系统疾病的预防与治疗中。本文主要综述他汀类药物在改善内皮细胞功能,抑制细胞增殖、抗炎、促骨质形成等方面的应用进展。     

他汀类药物的降脂外心血管保护作用

他汀类药物是预防和改善动脉粥样硬化性心血管疾病的主要药物,其主要通过降低血清胆固醇水平抑制动脉粥样硬化.但现有证据包括ASCOT、PRINCE、CARE及REVERSAL等研究均提示,他汀类药物具有显著的抗炎效应,尤其可显著降低c反应蛋白(CRP)水平,因而,抗炎效应也是其重要的抗动脉粥样硬化机制之一.他汀类药物还具有抗凝等心血管保护作用.     

CYP450基因多态性对他汀类药物个体化治疗影响的研究进展

他汀类药物通过降低血脂浓度、稳定粥样斑块及抗炎、抗氧化、调节失代偿内皮功能等多效效应发挥心血管保护作用,广泛应用于冠心病一级预防和二级预防。细胞色素P450酶是他汀类药物重要的代谢酶,其基因多态性是他汀类药物个体间代谢、血药浓度及降脂作用差异的重要原因之一。因此预测CYP450基因上与他汀代谢相关重要单核苷酸多态可能是实现他汀类药物个体化治疗的重要手段之一。本文将着重介绍与绝大多数他汀类药物代谢密切相关的CYP3A4、CYP3A5、CYP2C9、CYP2D6基因单核苷酸多态性(singlenucleotide polymorphisms,SNPs)及与他汀类药物转运及作用靶点相关基因单核苷酸多态。     

他汀类药物预防治疗脑卒中的临床价值

他汀类药物在预防治疗脑卒中所展现出的良好疗效和潜力已得到了临床的普遍认可,本文结合他汀类药物在预防治疗脑卒中的临床应用研究现状,对其预防治疗脑卒中的作用机制、安全用药、应用前景等方面进行综述。     

他汀类药物降脂作用外的临床新进展

目的：介绍他汀类降脂作用外的临床新进展。方法：参阅相关文献，经综合、分析和归纳。结果：他汀类药物具有预防心血管疾病，保护肾脏细胞，抗肿瘤细胞的增殖作用，抗癌中的增敏及减少不良反应，抗骨质疏松，预防痴呆，免疫抑制作用等。结论：他汀类药物在临床上具有广阔的应用前景。     

The Many Roles of Statins in Ischemic Stroke

Stroke is the third leading cause of human death. Endothelial dysfunction, thrombogenesis, inflammatory and oxidative stress damage, and angiogenesis play an important role in cerebral ischemic pathogenesis and represent a target for prevention and treatment. Statins have been found to improve endothelial function, modulate thrombogenesis, attenuate inflammatory and oxidative stress damage, and facilitate angiogenesis far beyond lowering cholesterol levels. Statins have also been proved to significantly decrease cardiovascular risk and to improve clinical outcome. Could statins be the new candidate agent for the prevention and therapy in ischemic stroke? In recent years, a vast expansion in the understanding of the pathophysiology of ischemic stroke and the pleiotropic effects of statins has occurred and clinical trials involving statins for the prevention and treatment of ischemic stroke have begun. These facts force us to revisit ischemic stroke and consider new strategies for prevention and treatment. Here, we survey the important developments in the non-lipid dependent pleiotropic effects and clinical effects of statins in ischemic stroke.     

The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective

The available therapeutic options for sepsis are restricted by their effectiveness and high cost. Emerging preliminary data suggest that statins and omega-3 fatty acids (OM3FA) may be associated with improved outcomes in terms of prevention and treatment of sepsis. We sought to review the current evidence on the effectiveness of their combined administration against sepsis, by carrying out a review of PubMed and Scopus databases for relevant studies, without imposing language or time restrictions. No clinical studies were identified regarding the effect of the combination treatment with statins and OM3FA on sepsis in terms of prevention or treatment. However, there is experimental evidence that both statins and OM3FA inhibit the inflammatory process at different levels, but also enhance inhibition at those levels that are common. There are also preliminary data supporting the beneficial effect of this combination on platelet function and other haemostatic mechanisms. Appropriately designed and powered clinical trials are warranted to investigate the effectiveness and safety of the combined administration of statins and OM3FA for the prevention and treatment of sepsis.     

基于生物信息技术预警他汀类药物防治动脉粥样硬化安全风险

目的 通过生物信息技术探讨他汀类药物治疗动脉粥样硬化潜在的安全风险.方法 采用生物信息技术提取GEO数据库中的基因芯片数据集GSE32547,对他汀类药物干预人脐静脉内皮细胞差异表达基因进行基因本体注释、信号通路分析以及蛋白质互作网络分析,以探讨其用药风险预警.结果 生物信息分析结果 显示,他汀类药物治疗动脉粥样硬化时...     

The beneficial effects of statins in autoimmune disease therapy

Statins, HMG-CoA reductase inhibitors, are widely used for the treatment of hypercholesterolemia and the prevention of cardiovascular diseases. Recent experimental and clinical studies evaluated the effect of statins on immune and inflammatory cells, and the efficacy of statins in treatment of immune diseases. This review discusses the roles of statins in the treatment of immune and inflammatory diseases.     

他汀类药物致药物性肝损伤的研究进展

他汀类药物调脂作用显著,是一类较全面的调脂药,能强效降低血清总胆固醇(TC)和低密度脂蛋白(LDL),在心血管疾病预防和治疗中应用广泛。近年来,随着他汀类药物的广泛应用,对其不良反应的研究也日趋深入。肝毒性是此类药物产生的重要不良反应之一,他汀类药物在使用过程中偶有药物性肝损伤(DILI)发生,对他汀类药物致DILI影响因素、相关机制及防治策略的研究进展进行总结,旨在为他汀类药物临床合理使用及DILI的预防提供依据。     

The impact of statin treatment on diabetic patients

Retrospective analysis of secondary prevention trials indicates that 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors (statins) reduce the risk of recurrent coronary heart disease events in individuals with diabetes. Diabetic individuals may receive greater benefit from statin treatment than non-diabetic individuals, because of a higher absolute risk. Available data are limited, although several randomized trials of primary prevention with diabetic patients are ongoing. The low-density lipoprotein cholesterol goal is now considered to be < 100 mg/dl for individuals with diabetes. Pleiotropic effects of statins may be involved in anti-atherogenic or other actions of statin.     

2010调脂治疗领域进展

2010年在调脂治疗领域针对他汀治疗心血管病的防治又进行了许多探索。本文通过综述他汀类药物的国际大规模临床试验结果,重新评价了他汀类药物在冠心病一级预防和冠心病二级预防中的地位,阐明了强化他汀治疗的意义;对他汀的心肾保护作用和安全性新证据进行了说明。     

Statins and dilated cardiomyopathy: do we have enough data?

INTRODUCTION: Dilated cardiomyopathy (DCM) is a multifactorial disease in which there is enlargement and systolic dysfunction of one or both ventricles. The exhaustion of compensatory mechanisms leads to the symptoms of congestive heart failure (CHF). Despite treatment, CHF is a progressive disease with high morbidity and mortality, suggesting that important pathogenic mechanisms remain active and unmodified by currently available treatment. AREAS COVERED: Several lines of evidence suggest that inflammation plays a role in the development and progression of CHF, influencing heart contractility and hypertrophy, promoting apoptosis and contributing to myocardial remodeling. More general immunomodulating treatments, such as statins, have shown promising results in patients with cardiomyopathies. MEDLINE (1966 - May 2010), EMBASE and SCOPUS (1965 - May 2010) and DARE (1966 - May 2010) were searched, in addition to abstracts from national and international cardiovascular meetings. The main data search terms were: dilated cardiomyopathy, dyslipidemia, heart failure, left ventricle dysfunction and statins. EXPERT OPINION: Inhibition of inflammation, alleviating endothelial damage and reducing endothelial dysfunction might comprise part of the underlying mechanisms leading to the improvement of left ventricular function and exercise tolerance in patients with DCM. Candidates for statin therapy with DCM should be in New York Heart Association class II or III and should have normal or increased levels of lipids.     

Statins and the Reduction of Sudden Cardiac Death

Sudden cardiac death is an important cause of cardiovascular mortality with the majority of cases occurring in low-risk groups. HMG-CoA reductase inhibitors (statins) have recently been shown to reduce the incidence of ventricular tachycardia (VT)/fibrillation (VF) and sudden cardiac death, and this has been attributed to their pleiotropic effects. However, it is unclear whether this occurs through an ‘indirect’ anti-ischemic or ‘direct’ antiarrhythmic effect. We systematically reviewed articles published on MEDLINE between January 1996 and December 2009 focusing on the reduction of VT/VF and sudden cardiac death by statins and the potential mechanisms. Studies reporting sudden cardiac death or VT/VF outcomes with statin use (n = 23) or the pathophysiology of sudden cardiac death reduction by statins (n = 19) were included. We found that statins have been shown to reduce VT/VF and sudden cardiac death only in subjects with underlying coronary artery disease or ischemic cardiomyopathy. No definite benefits were seen with statins in sudden cardiac death and VT/VF in patients with non-ischemic cardiomyopathy. There is insufficient evidence to point toward a benefit in populations at low risk for VT/VF. In conclusion, an anti-ischemic rather than a primary antiarrhythmic effect emerges as the likely mechanism of sudden cardiac death reduction with statins.